These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 10366018)

  • 1. Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function.
    Alonso R; Voutsinos B; Fournier M; Labie C; Steinberg R; Souilhac J; Le Fur G; Soubrié P
    Neuroscience; 1999; 91(2):607-20. PubMed ID: 10366018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior.
    Duarte C; Alonso R; Bichet N; Cohen C; Soubrié P; Thiébot MH
    Neuropsychopharmacology; 2004 May; 29(5):911-20. PubMed ID: 14694354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats.
    Cohen C; Perrault G; Voltz C; Steinberg R; Soubrié P
    Behav Pharmacol; 2002 Sep; 13(5-6):451-63. PubMed ID: 12394421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of neurotensin receptors suppresses the dopamine D1/D2 synergism on immediate early gene expression in the rat brain.
    Alonso R; Gnanadicom H; Fréchin N; Fournier M; Le Fur G; Soubrié P
    Eur J Neurosci; 1999 Mar; 11(3):967-74. PubMed ID: 10103090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine D3 receptors are not involved in the induction of c-fos mRNA by neuroleptic drugs: comparison of the dopamine D3 receptor antagonist GR103691 with typical and atypical neuroleptics.
    Hurley MJ; Stubbs CM; Jenner P; Marsden CD
    Eur J Pharmacol; 1996 Dec; 318(2-3):283-93. PubMed ID: 9016916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization.
    Deutch AY; Duman RS
    Neuroscience; 1996 Jan; 70(2):377-89. PubMed ID: 8848147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of morphine-induced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716.
    Singh ME; Verty AN; Price I; McGregor IS; Mallet PE
    Neuropharmacology; 2004 Dec; 47(8):1157-69. PubMed ID: 15567425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the D(3) dopamine receptor antagonist, U99194A, on brain stimulation and d-amphetamine reward, motor activity, and c-fos expression in ad libitum fed and food-restricted rats.
    Carr KD; Yamamoto N; Omura M; Cabeza de Vaca S; Krahne L
    Psychopharmacology (Berl); 2002 Aug; 163(1):76-84. PubMed ID: 12185403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of the cannabinoid CB1 receptor in modulation of dopamine output in the prefrontal cortex associated with food restriction in rats.
    Dazzi L; Talani G; Biggio F; Utzeri C; Lallai V; Licheri V; Lutzu S; Mostallino MC; Secci PP; Biggio G; Sanna E
    PLoS One; 2014; 9(3):e92224. PubMed ID: 24632810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain.
    Porcella A; Gessa GL; Pani L
    Eur J Neurosci; 1998 May; 10(5):1743-51. PubMed ID: 9751146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated exposure to cocaine alters medial prefrontal cortex dopamine D₂-like receptor modulation of glutamate and dopamine neurotransmission within the mesocorticolimbic system.
    Liu K; Steketee JD
    J Neurochem; 2011 Oct; 119(2):332-41. PubMed ID: 21692802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid-induced Fos expression within A10 dopaminergic neurons.
    Patel S; Hillard CJ
    Brain Res; 2003 Feb; 963(1-2):15-25. PubMed ID: 12560108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reserpine increases Fos activity in the rat basal ganglia via a quinpirole-sensitive mechanism.
    Cole DG; Di Figlia M
    Neuroscience; 1994 May; 60(1):115-23. PubMed ID: 7914358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions.
    Gygi SP; Gibb JW; Hanson GR
    J Pharmacol Exp Ther; 1994 Jul; 270(1):192-7. PubMed ID: 7913495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SR141716, a CB1 receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats.
    Deroche-Gamonet V; Le Moal M; Piazza PV; Soubrié P
    Psychopharmacology (Berl); 2001 Sep; 157(3):254-9. PubMed ID: 11605080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of c-fos mRNA in rat medial prefrontal cortex by antipsychotic drugs: role of dopamine D2 and D3 receptors.
    Merchant KM; Figur LM; Evans DL
    Cereb Cortex; 1996; 6(4):561-70. PubMed ID: 8670682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.
    Maneuf YP; Crossman AR; Brotchie JM
    Exp Neurol; 1997 Nov; 148(1):265-70. PubMed ID: 9398468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered dopaminergic function in the prefrontal cortex, nucleus accumbens and caudate-putamen of an animal model of attention-deficit hyperactivity disorder--the spontaneously hypertensive rat.
    Russell V; de Villiers A; Sagvolden T; Lamm M; Taljaard J
    Brain Res; 1995 Apr; 676(2):343-51. PubMed ID: 7614004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.
    Tzavara ET; Davis RJ; Perry KW; Li X; Salhoff C; Bymaster FP; Witkin JM; Nomikos GG
    Br J Pharmacol; 2003 Feb; 138(4):544-53. PubMed ID: 12598408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.
    Huestis MA; Gorelick DA; Heishman SJ; Preston KL; Nelson RA; Moolchan ET; Frank RA
    Arch Gen Psychiatry; 2001 Apr; 58(4):322-8. PubMed ID: 11296091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.